News: stock, crypto, macro, education

CVS Health Announces Q1 2024 Financial Results and Updates Full-Year Guidance Amidst Stock Decline

CVS Health Announces Q1 2024 Financial Results and Updates Full-Year Guidance Amidst Stock Decline

CVS Health Corporation has released its earnings for the first quarter of 2024, showcasing a mixed financial performance that has led to a sharp 16% drop in its stock price. The company reported total revenues of $88.4 billion, marking a 3.7% increase from the previous year. However, both GAAP and adjusted earnings per share saw significant declines.

Key Financial Metrics

  • Total Revenues: Increased to $88.4 billion, up 3.7%.
  • GAAP Diluted EPS: Decreased to $0.88 from $1.65 year-over-year.
  • Adjusted EPS: Lowered to $1.31 from $2.20 in the prior year.
  • Cash Flow from Operations: Generated $4.9 billion in the quarter.

Revised 2024 Full-Year Guidance

CVS Health has revised its full-year 2024 guidance, reflecting the challenges faced in the first quarter, particularly in the Medicare Advantage sector.

Updated Guidance Details

  • GAAP Diluted EPS: Revised down to at least $5.64 from previous guidance of at least $7.06.
  • Adjusted EPS: Lowered to at least $7.00 from an initial forecast of at least $8.30.
  • Cash Flow from Operations: Updated to at least $10.5 billion, down from earlier expectations of at least $12.0 billion.

CEO's Commentary on Financial Performance

Karen S. Lynch, President and CEO of CVS Health, commented on the results, emphasizing confidence in the company’s long-term strategy despite current challenges. She highlighted the company’s continued commitment to delivering value to various stakeholders and addressing near-term challenges in the Medicare Advantage program.

More articles